NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen announced that its board has initiated a share buyback plan on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.

Biogen Inc (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, October, 22nd. The biotechnology company reported $9.17 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $8.27 by $0.90. The biotechnology company had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.53 billion. Biogen had a net margin of 37.91% and a return on equity of 46.14%. The business's revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.40 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Biogen.

Biogen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

34 Wall Street analysts have issued twelve-month target prices for Biogen's shares. Their forecasts range from $230.00 to $365.00. On average, they expect Biogen's stock price to reach $288.72 in the next year. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Biogen.

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 21 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

News headlines about BIIB stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biogen earned a news impact score of -2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Boeing (BA).

Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.26%), Candriam Luxembourg S.C.A. (0.22%), Tocqueville Asset Management L.P. (0.08%), Wedge Capital Management L L P NC (0.07%), DNB Asset Management AS (0.06%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Candriam Luxembourg S.C.A., Artemis Investment Management LLP, Gateway Investment Advisers LLC, Wedge Capital Management L L P NC, Country Trust Bank and OLD National Bancorp IN. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Rhenman & Partners Asset Management AB, Alpine Global Management LLC, Abner Herrman & Brock LLC, Wealthfront Advisers LLC, Baxter Bros Inc., FormulaFolio Investments LLC and Balasa Dinverno & Foltz LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $290.65.

Biogen has a market capitalization of $52.44 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.View Additional Information About Biogen.

The official website for Biogen is http://www.biogen.com/.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]